Baxter International Inc. (BAX): Price and Financial Metrics
Baxter International Inc. (BAX)
Today's Latest Price: $77.98 USD
Updated Dec 4 12:34pm
Add BAX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 143 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
BAX Stock Summary
- BAX has a market capitalization of $39,000,984,687 -- more than approximately 94.4% of US stocks.
- BAX's went public 34.95 years ago, making it older than 92.99% of listed US stocks we're tracking.
- In terms of volatility of its share price, BAX is more volatile than only 1.16% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Baxter International Inc, a group of peers worth examining would be A, IDXX, ALGN, CSGP, and RMD.
- BAX's SEC filings can be seen here. And to visit Baxter International Inc's official web site, go to www.baxter.com.
BAX Stock Price Chart Interactive Chart >
BAX Price/Volume Stats
| Current price | $77.98 | 52-week high | $95.19 |
| Prev. close | $76.32 | 52-week low | $69.10 |
| Day low | $76.10 | Volume | 1,093,408 |
| Day high | $78.00 | Avg. volume | 3,149,586 |
| 50-day MA | $79.19 | Dividend yield | 1.28% |
| 200-day MA | $83.55 | Market Cap | 39.83B |
Baxter International Inc. (BAX) Company Bio
Baxter International provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, biosurgery products and anesthetics, and pharmacy automation, software and services. The company was founded in 1931 and is based in Deerfield, Illinois.
BAX Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $77.98 | $21.04 | -72% |
We started the process of determining a valid price forecast for Baxter International Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Baxter International Inc ranked in the 21th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 72.33%. The most interesting components of our discounted cash flow analysis for Baxter International Inc ended up being:
- The company's compound free cash flow growth rate over the past 5.68 years comes in at 0%; that's greater than only 24.89% of US stocks we're applying DCF forecasting to.
- BAX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 25.99% of tickers in our DCF set.
- The weighted average cost of capital for the company is 8. This value is greater than merely 20.69% stocks in the Healthcare sector that generate free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -73% |
| 1% | -73% |
| 2% | -72% |
| 3% | -72% |
| 4% | -72% |
| 5% | -72% |
MTD, PRGO, AZN, ENDP, and RHE can be thought of as valuation peers to BAX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...